TherapeuticsMD (TXMD) AI Stock Analysis

2,250 Followers

TherapeuticsMD

(NASDAQ:TXMD)

Select Model

Rating:55Neutral

Price Target:$2.00▲(8.11% Upside)

Action:reiterated

Date:08/26/26

The score is driven primarily by improving financial stability (positive free cash flow and manageable leverage) but is held back by weak operating performance (small, declining revenue and negative EBIT/EBITDA). Technicals are moderately supportive due to an uptrend, though the overbought RSI adds near-term risk. Valuation remains unattractive/unclear given the negative P/E, and corporate developments add uncertainty due to the strategic alternatives review.

Positive Factors

Positive Cash GenerationPositive operating and free cash flow mark a meaningful recovery from deeply negative operating cash flow in 2023. This improves the company’s ability to fund ongoing activities internally, supports financial resilience, and reduces immediate dependence on external capital while operations remain under pressure.

Negative Factors

Declining Revenue BaseA small and declining revenue base weakens operating leverage and makes performance more dependent on individual licensing or product events. Unless revenue stabilizes and expands, the company may struggle to support its cost structure, sustain investment, and convert its portfolio into durable earnings.

TherapeuticsMD (TXMD) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $21.41M
Dividend Yield: ―
Average Volume (3M): 23.93K
Price to Earnings (P/E): -98.4
Beta (1Y): 1.15
Revenue Growth: 27.78%
EPS Growth: 52.88%
Country: US
Employees: 1
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

TherapeuticsMD Business Overview & Revenue Model

Company Description

TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradi...

How the Company Makes Money

TherapeuticsMD has generated revenue primarily through out-licensing/partnering arrangements for its product portfolio rather than through building a fully integrated, long-term direct commercial sales model. Under these types of agreements, the comp...

TherapeuticsMD Financial Statement Overview

Summary

Financials show a recovery but remain mixed. Cash flow has turned positive (operating cash flow and free cash flow both $3.12M TTM) and the balance sheet is relatively stable with low leverage (debt-to-equity ~0.20). However, the income statement is still the weak point: revenue is small ($3.27M TTM) and declining, and operating profitability remains negative (EBIT/EBITDA materially negative), keeping execution risk elevated.

Income Statement

28Negative

Balance Sheet

64Positive

Cash Flow

70Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Mar 2023	Dec 2021
Income Statement
Total Revenue	3.27M	3.02M	1.76M	1.30M	69.96M	2.57M
Gross Profit	2.94M	3.02M	1.76M	1.30M	68.57M	1.17M
EBITDA	-3.96M	-3.02M	-4.33M	-7.60M	11.86M	-78.84M
Net Income	-217.00K	-569.00K	-2.18M	-10.28M	112.00M	-172.41M
Balance Sheet
Total Assets	37.53M	37.66M	38.82M	43.31M	90.46M	169.47M
Cash, Cash Equivalents and Short-Term Investments	9.19M	7.48M	5.06M	4.33M	38.07M	64.91M
Total Debt	5.56M	6.10M	7.17M	8.01M	8.76M	197.69M
Total Liabilities	10.40M	10.78M	11.45M	14.02M	55.31M	263.09M
Stockholders Equity	27.13M	26.88M	27.37M	29.29M	35.14M	-93.62M
Cash Flow
Free Cash Flow	3.12M	2.42M	732.00K	0	-4.43M	-147.84M
Operating Cash Flow	3.12M	2.42M	732.00K	-48.14M	-4.08M	-147.81M
Investing Cash Flow	0	0	0	0	223.48M	-2.22M
Financing Cash Flow	0	0	0	3.15M	-235.21M	134.67M

TherapeuticsMD Technical Analysis

Technical Analysis SentimentNeutral

Last Price1.85

Price Trends

50DMA1.99Negative

100DMA2.03Negative

200DMA2.09Negative

Market Momentum

MACD-0.06Negative

RSI49.48Neutral

STOCH62.10Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TXMD, the sentiment is Neutral. The current price of 1.85 is above the 20-day moving average (MA) of 1.81, below the 50-day MA of 1.99, and below the 200-day MA of 2.09, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 49.48 is Neutral, neither overbought nor oversold. The STOCH value of 62.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TXMD.

TherapeuticsMD Risk Analysis

TherapeuticsMD disclosed 49 risk factors in its most recent earnings report. TherapeuticsMD reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

TherapeuticsMD Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

TXMD against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AYTU	61Neutral	$19.67M	-1.32	-52.89%	―	-13.27%	27.11%
TXMD	55Neutral	$20.14M	-98.40	-0.80%	―	27.78%	52.88%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RDHL	42Neutral	$3.33M	-0.37	-438.17%	―	―	―
PRPH	41Neutral	$100.57K	-0.00	-1358.66%	―	―	―

* Healthcare Sector Average

Performance Comparison

TXMD and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TXMD	Therapeuticsmd Inc	1.85	0.23	14.20%
PRPH	Prophase Labs	0.01	-2.51	-99.60%
RDHL	RedHill Biopharma Ltd	0.37	-0.70	-65.79%
AYTU	Aytu BioScience	1.81	-0.25	-12.14%
GELS	Gelteq Limited	0.42	-0.59	-58.42%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 26, 2026

TherapeuticsMD AI Stock Analysis